Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil

By Weycker Derek   Taneja Charu   Edelsberg John   Erder M. Haim   Schmitt Frederick A.   Setyawan Juliana   Oster Gerry  

Current Medical Research and Opinion, Vol. 23, Iss. 5, 2007-05 ,pp. : 1187-1197

Informa Healthcare

Access to resources Recommend Favorite

Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials

By Winblad Bengt   Black Sandra E.   Homma Akira   Schwam Elias M.   Moline Margaret   Xu Yikang   Perdomo Carlos A.   Swartz Jina   Albert Kenneth  

Current Medical Research and Opinion, Vol. 25, Iss. 11, 2009-11 ,pp. : 2577-2587

Informa Healthcare

Access to resources Recommend Favorite

Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study

By Aupperle Peter M.   Koumaras Barbara   Chen Michael   Rabinowicz Adrian   Mirski Dario  

Current Medical Research and Opinion, Vol. 20, Iss. 10, 2004-10 ,pp. : 1605-1612

Informa Healthcare

Access to resources Recommend Favorite

Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease

By Bullock Roger   Bergman Howard   Touchon Jacques   Gambina Giuseppe   He Yunsheng   Nagel Jennifer   Lane Roger  

Current Medical Research and Opinion, Vol. 22, Iss. 3, 2006-03 ,pp. : 483-494

Informa Healthcare

Access to resources Recommend Favorite

Impact of donepezil treatment for Alzheimer's disease on caregiver time

By Wimo Anders   Winblad Bengt   Shah Sonali N.   Chin Warren   Zhang Richard   McRae Thomas  

Current Medical Research and Opinion, Vol. 20, Iss. 8, 2004-08 ,pp. : 1221-1225

Informa Healthcare

Access to resources Recommend Favorite